TY - CHAP M1 - Book, Section TI - Colorectal Cancer A1 - Holle, Lisa M. A1 - Clement, Jessica M. A1 - Davis, Lisa E. A2 - DiPiro, Joseph T. A2 - Yee, Gary C. A2 - Posey, L. Michael A2 - Haines, Stuart T. A2 - Nolin, Thomas D. A2 - Ellingrod, Vicki Y1 - 2020 N1 - T2 - Pharmacotherapy: A Pathophysiologic Approach, 11e AB - Update SummaryThe following updates to this chapter were made on February 7, 2021:Metastatic Disease Initial Therapy section and Table 147-6 updated: Removed fluorouracil/leucovorin + bevacizumab and capecitabine + bevacizumab as no longer recommended as first-line therapy in patients appropriate for intensive therapy; added pembrolizumab for patients with dMMR/MSI-H appropriate for intensive therapy; updated dosing intervals for checkpoint inhibitors; and added trastuzumab + [pertuzumab or lapatinib] for patients not appropriate for intensive therapy with HER amplified and RAS and BRAF WTTable 147-7 in Metastatic Disease: Second-Line and Subsequent Therapy section updated: Removed binimetinib as no longer recommended in combination with encorafenib if BRAF V600 mutation positive; removed section on second-line options following first-line fluorouracil-based regimens; and added regimens for BRAF V600 mutation mutation-positive patients for second- or subsequent-line regimens SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accesspharmacy.mhmedical.com/content.aspx?aid=1191342176 ER -